EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer – The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629)

Ralf-Dieter Hofheinz, Ludwig Fischer von Weikersthal, Tobias Dechow, Reinhard Depenbusch, Christian Müller, Thorsten O Goetze, Silvan Becker, Alexander Kiani, Thomas Ettrich, Alexander Schmittel, Holger Schulz, Matthias Ebert und 6 weitere

European Journal of Cancer · 2026-05 · 239 · 116689

DOI: 10.1016/j.ejca.2026.116689 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-05. Verfasst von Ralf-Dieter Hofheinz und 17 weiteren Autor:innen. Beteiligte Einrichtung: Mannheim Cancer Center, Universitätsmedizin Mannheim, Mannheim, Germany. Electronic address: ralf.hofheinz@umm.de. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Recombinant Fusion Proteins. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi-Aventis Deutschland GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Fluoropyrimidines + angiogenesis inhibitor or dose-reduced doublets are used for (frail) elderly patients with metastatic colorectal cancer (mCRC). This non-comparative trial evaluated two 1st line regimens for patients not eligible for full-dose combinations. METHODS: This open-label, multicenter, phase II study randomized untreated mCRC patients ≥ 70 years ± frailty 1:1 to dose reduced mFOLFOX7 in Arm A or aflibercept (4 mg/kg) plus dose reduced mLV5FU2 in Arm B. Primary endpoint was the 6-months PFS rate (PFS@6), secondary endpoints included safety, overall survival (OS), overall response rate (ORR), patient reported outcomes and overall treatment utility (OTU). FINDINGS: The full analysis population comprised 120 patients (62 Arm A, 58 Arm B; 63% male), with a median age of 78.5 years. 82% frail patients were included. PFS@6 was 68% [95%CI 56%;80%] in Arm A and 46% [32%;59%] in Arm B. Median PFS was 7.9 and 5.5 months, median OS was 20.4 and 19.0 months and ORR was 47% and 22% in Arm A and B, respectively. At 3 months, 52% in Arm A and 35% in Arm B had a good OTU. Most frequent grade ≥ 3 AEs in Arm B were hypertension (41%) and proteinuria (10%). More patients in arm B had treatment-related SAEs grade ≥ 3 (17% in arm B and 5% in arm A). INTERPRETATION: Both regimens were feasible in this (frail) elderly population. Dose-reduced mFOLFOX7 and, to a lesser extent, 5-FU/aflibercept showed good PFS and 3-month OTU. Although most patients were regarded frail, survival rates were promising, most likely due to effective further-line treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsRecombinant Fusion ProteinsAgedAged, 80 and overFemaleHumansMaleFluorouracilFrail ElderlyLeucovorinOrganoplatinum CompoundsReceptors, Vascular Endothelial Growth Factor

Stichwörter der Autor:innen

AfliberceptElderly patientsFrailtyMetastatic colorectal cancerOxaliplatin

Substanzen

afliberceptFluorouracilLeucovorinOrganoplatinum CompoundsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Mannheim Cancer Center, Universitätsmedizin Mannheim, Mannheim, Germany. Electronic address: ralf.hofheinz@umm.de.
  • MVZ-Praxis für Hämatologie und Internistische Onkologie, Amberg, Germany.
  • Gemeinschaftspraxis für Hämatologie und Onkologie, Ravensburg, Germany.
  • Onkologische Gemeinschaftspraxis, Gütersloh, Germany.
  • Internistische Onkologie, Evangelische Kliniken Essen-Mitte, Essen, Germany.
  • Krankenhaus Nordwest, University Cancer Center Frankfurt, Frankfurt, Germany; Frankfurter Institut für Klinische Krebsforschung IKF GmbH, Frankfurt am Main, Germany.

Förderung

  • Sanofi-Aventis Deutschland GmbH

Zitieren

APA

Hofheinz, R. D., Weikersthal, L. F. V., Dechow, T., Depenbusch, R., Müller, C., Goetze, T. O., Becker, S., Kiani, A., Ettrich, T., Schmittel, A., Schulz, H., Ebert, M., Sookthai, D., Volk, C., Pauligk, C., Loose, M., Al-Batran, S. E., & Lorenzen, S. (2026). Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer – The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629). European Journal of Cancer, 239, 116689. https://doi.org/10.1016/j.ejca.2026.116689

Vancouver

Hofheinz RD, Weikersthal LFV, Dechow T, Depenbusch R, Müller C, Goetze TO, et al. Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer – The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629). European Journal of Cancer. 2026;239:116689. doi:10.1016/j.ejca.2026.116689

BibTeX
@article{Hofheinz2026,
  author = {Hofheinz, Ralf-Dieter and Weikersthal, Ludwig Fischer von and Dechow, Tobias and Depenbusch, Reinhard and Müller, Christian and Goetze, Thorsten O and Becker, Silvan and Kiani, Alexander and Ettrich, Thomas and Schmittel, Alexander and Schulz, Holger and Ebert, Matthias and Sookthai, Disorn and Volk, Claudia and Pauligk, Claudia and Loose, Maria and Al-Batran, Salah-Eddin and Lorenzen, Sylvie},
  title = {Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer – The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629)},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {239},
  pages = {116689},
  doi = {10.1016/j.ejca.2026.116689}
}
Kostenlos starten →